Newron Pharmaceuticals SpA (XSWX:NWRN) ROCE %

: -233.82% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Newron Pharmaceuticals SpA's annualized ROCE % for the quarter that ended in Dec. 2023 was -233.82%.

Newron Pharmaceuticals SpA ROCE % Historical Data

The historical data trend for Newron Pharmaceuticals SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newron Pharmaceuticals SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-34.94

-34.91

-25.78

-33.17

-78.67

Newron Pharmaceuticals SpA Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %																-19.80	-30.86	-37.02	-41.59	-233.82

Newron Pharmaceuticals SpA ROCE % Calculation

Newron Pharmaceuticals SpA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.347	/	( ( (36.706 - 4.975)	+	(24.394 - 27.279) )	/ 2 )
	=	-11.347	/	( (31.731	+	-2.885)	/ 2 )
	=	-11.347	/	14.423
	=	-78.67 %

Newron Pharmaceuticals SpA's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-13.428	/	( ( (30.723 - 16.352)	+	(24.394 - 27.279) )	/ 2 )
	=	-13.428	/	( ( 14.371	+	-2.885 )	/ 2 )
	=	-13.428	/	5.743
	=	-233.82 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Newron Pharmaceuticals SpA (XSWX:NWRN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Newron Pharmaceuticals SpA ROCE % Related Terms

Thank you for viewing the detailed overview of Newron Pharmaceuticals SpA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Newron Pharmaceuticals SpA (XSWX:NWRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Newron Pharmaceuticals SpA (XSWX:NWRN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NWPHF:USA NP5:Germany

Address

Via Antonio Meucci 3, Bresso, Milan, ITA, 20091

Website

https://www.newron.com

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.

Executives

Patrick Langlois

Supervisory Board

Newron Pharmaceuticals SpA (XSWX:NWRN) Headlines

No Headlines